AUTL — Autolus Therapeutics Share News
0.000.00%
Last trade - 00:00- $428.49m
- $476.32m
- $75.39m
Brief: Autolus Therapeutics Appoints Ryan Richardson To Board Of Directors
Brief: Nice Recommends Aucatzyl As A Treatment Option For Adult Patients With Lymphoblastic Leukemia
Brief: Autolus Therapeutics’ Car T Therapy Aucatzyl® (Obecabtagene Autoleucel) Granted European Marketing Authorization For Adult Patients
Brief: Autolus Therapeutics Announces Inducement Grants
Brief: EMA's CHMP Says Positive Opinion Was Adopted For Blenrep - Website
Brief: Autolus Therapeutics PLC Files For Resale Of Up To 54.6 Million American Depositary Shares By The Selling Securityholders - SEC Filing
Autolus Therapeutics rises on US FDA approval for its cancer cell therapy
Brief: Autolus Therapeutics Announces FDA Approval Of Aucatzyl® (Obecabtagene Autoleucel – Obe-Cel) For Adults With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-All)
Brief: FDA Approves Obecabtagene Autoleucel For Adults With Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Brief: Autolus Therapeutics Announces Changes To Its Board Of Directors
Autolus Therapeutics PLC reports results for the quarter ended in December - Earnings Summary
J&J, 2seventy bio fall after US FDA raises concerns over CAR-T therapy data
Brief: Autolus Therapeutics Receives MHRA Certification For Nucleus Commercial Manufacturing Site
Autolus Therapeutics PLC expected to post a loss of 25 cents a share - Earnings Preview
Autolus Therapeutics PLC expected to post a loss of 25 cents a share - Earnings Preview
Brief: Biontech SE Reports 12.5% Stake In Autolus Therapeutics PLC As Of February 13, 2024
U.S. STOCKS ON THE MOVE-S&P Global, Hershey, Under Armour
U.S. STOCKS ON THE MOVE-ConocoPhillips, Advanced Drainage Systems, Molina Healthcare
U.S. STOCKS ON THE MOVE-Kenvue, Tapestry, Ralph Lauren